Literature DB >> 25741791

The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.

James R Arndt, Maxmore Chaibva, Justin Legleiter.   

Abstract

Huntington's disease (HD) is caused by a polyglutamine (polyQ) domain that is expanded beyond a critical threshold near the N-terminus of the huntingtin (htt) protein, directly leading to htt aggregation. While full-length htt is a large (on the order of ∼350 kDa) protein, it is proteolyzed into a variety of N-terminal fragments that accumulate in oligomers, fibrils, and larger aggregates. It is clear that polyQ length is a key determinant of htt aggregation and toxicity. However, the flanking sequences around the polyQ domain, such as the first 17 amino acids on the N terminus (Nt17), influence aggregation, aggregate stability, influence other important biochemical properties of the protein and ultimately its role in pathogenesis. Here, we review the impact of Nt17 on htt aggregation mechanisms and kinetics, structural properties of Nt17 in both monomeric and aggregate forms, the potential role of posttranslational modifications (PTMs) that occur in Nt17 in HD, and the function of Nt17 as a membrane targeting domain.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25741791      PMCID: PMC4590289          DOI: 10.1515/bmc-2015-0001

Source DB:  PubMed          Journal:  Biomol Concepts        ISSN: 1868-5021


  158 in total

1.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

2.  Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes.

Authors:  Nihar Ranjan Jana; Priyanka Dikshit; Anand Goswami; Svetlana Kotliarova; Shigeo Murata; Keiji Tanaka; Nobuyuki Nukina
Journal:  J Biol Chem       Date:  2005-01-21       Impact factor: 5.157

3.  An acylation cycle regulates localization and activity of palmitoylated Ras isoforms.

Authors:  Oliver Rocks; Anna Peyker; Martin Kahms; Peter J Verveer; Carolin Koerner; Maria Lumbierres; Jürgen Kuhlmann; Herbert Waldmann; Alfred Wittinghofer; Philippe I H Bastiaens
Journal:  Science       Date:  2005-02-10       Impact factor: 47.728

4.  Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.

Authors:  David W Colby; Yijia Chu; John P Cassady; Martin Duennwald; Helen Zazulak; Jack M Webster; Anne Messer; Susan Lindquist; Vernon Martin Ingram; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-14       Impact factor: 11.205

5.  Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology.

Authors:  E Scherzinger; A Sittler; K Schweiger; V Heiser; R Lurz; R Hasenbank; G P Bates; H Lehrach; E E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

6.  A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.

Authors:  Flaviano Giorgini; Paolo Guidetti; QuangVu Nguyen; Simone C Bennett; Paul J Muchowski
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

7.  Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.

Authors:  F Persichetti; F Trettel; C C Huang; C Fraefel; H T Timmers; J F Gusella; M E MacDonald
Journal:  Neurobiol Dis       Date:  1999-10       Impact factor: 5.996

8.  A cellular model that recapitulates major pathogenic steps of Huntington's disease.

Authors:  A Lunkes; J L Mandel
Journal:  Hum Mol Genet       Date:  1998-09       Impact factor: 6.150

9.  Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

Authors:  F Saudou; S Finkbeiner; D Devys; M E Greenberg
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

10.  Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer.

Authors:  Jennifer L Wacker; M Hadi Zareie; Hanson Fong; Mehmet Sarikaya; Paul J Muchowski
Journal:  Nat Struct Mol Biol       Date:  2004-11-14       Impact factor: 15.369

View more
  19 in total

1.  Protofilament Structure and Supramolecular Polymorphism of Aggregated Mutant Huntingtin Exon 1.

Authors:  Jennifer C Boatz; Talia Piretra; Alessia Lasorsa; Irina Matlahov; James F Conway; Patrick C A van der Wel
Journal:  J Mol Biol       Date:  2020-06-27       Impact factor: 5.469

2.  Probing initial transient oligomerization events facilitating Huntingtin fibril nucleation at atomic resolution by relaxation-based NMR.

Authors:  Samuel A Kotler; Vitali Tugarinov; Thomas Schmidt; Alberto Ceccon; David S Libich; Rodolfo Ghirlando; Charles D Schwieters; G Marius Clore
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-11       Impact factor: 11.205

Review 3.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 4.  Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.

Authors:  Adewale Adegbuyiro; Faezeh Sedighi; Albert W Pilkington; Sharon Groover; Justin Legleiter
Journal:  Biochemistry       Date:  2017-02-21       Impact factor: 3.162

5.  Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties.

Authors:  Nathan Riguet; Anne-Laure Mahul-Mellier; Niran Maharjan; Johannes Burtscher; Marie Croisier; Graham Knott; Janna Hastings; Alice Patin; Veronika Reiterer; Hesso Farhan; Sergey Nasarov; Hilal A Lashuel
Journal:  Nat Commun       Date:  2021-11-12       Impact factor: 14.919

6.  Fractionation for Resolution of Soluble and Insoluble Huntingtin Species.

Authors:  Joseph Ochaba; Eva L Morozko; Jacqueline G O'Rourke; Leslie M Thompson
Journal:  J Vis Exp       Date:  2018-02-27       Impact factor: 1.355

7.  Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.

Authors:  Eva L Morozko; Joseph Ochaba; Sarah J Hernandez; Alice Lau; Isabella Sanchez; Iliana Orellana; Lexi Kopan; Joshua Crapser; Janet H Duong; Julia Overman; Silvia Yeung; Joan S Steffan; Jack Reidling; Leslie M Thompson
Journal:  J Huntingtons Dis       Date:  2018

8.  Acetylation within the First 17 Residues of Huntingtin Exon 1 Alters Aggregation and Lipid Binding.

Authors:  Maxmore Chaibva; Sudi Jawahery; Albert W Pilkington; James R Arndt; Olivia Sarver; Stephen Valentine; Silvina Matysiak; Justin Legleiter
Journal:  Biophys J       Date:  2016-07-26       Impact factor: 4.033

9.  Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects.

Authors:  Vicky Hakim-Eshed; Ayub Boulos; Chen Cohen-Rosenzweig; Libo Yu-Taeger; Tamar Ziv; Yong Tae Kwon; Olaf Riess; Hoa Huu Phuc Nguyen; Noam E Ziv; Aaron Ciechanover
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-16       Impact factor: 11.205

10.  Molecular and structural architecture of polyQ aggregates in yeast.

Authors:  Anselm Gruber; Daniel Hornburg; Matthias Antonin; Natalie Krahmer; Javier Collado; Miroslava Schaffer; Greta Zubaite; Christian Lüchtenborg; Timo Sachsenheimer; Britta Brügger; Matthias Mann; Wolfgang Baumeister; F Ulrich Hartl; Mark S Hipp; Rubén Fernández-Busnadiego
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.